Survanta
is a medication used for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants. It
contains the active ingredient beractant, which acts as a replacement for the natural pulmonary surfactant found in
the lungs.
The medication helps improve the expansion of the alveoli, reduces breathing difficulties in newborns, and supports
lung function during the first hours and days after birth. It is administered in a hospital setting by a specialized
medical team to ensure optimal therapeutic outcomes.
Composition of Survanta
Available Strengths and Presentations
Indications for Survanta
Treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Prevention of RDS in newborns at high risk of developing the condition.
Improvement of lung function in premature and underdeveloped infants.
Reduction of complications associated with pulmonary surfactant deficiency.
Support of respiratory function during the early neonatal period.
Dosage and Administration
The dose is determined according to the infant’s body weight, clinical condition, and the treating physician’s
assessment. The medication is administered directly into the trachea by qualified healthcare professionals. Additional
doses may be given when necessary based on the infant’s response and the established treatment plan.
Survanta is used exclusively in neonatal intensive care units (NICUs) under close medical supervision, with strict
adherence to approved protocols and clinical guidelines to ensure safe administration and effective treatment.
Side Effects of Survanta
Temporary slowing of the heart rate (bradycardia).
Transient decrease in oxygen levels during administration.
Temporary blockage of the endotracheal tube.
Changes in blood pressure.
Reflux of airway tube contents.
Temporary abnormal breath sounds.
Transient respiratory disturbances requiring medical monitoring.
Contraindications
There are no known absolute contraindications when the medication is used according to approved medical
recommendations. However, it should only be administered under specialist supervision in a hospital setting with
continuous monitoring of the infant’s respiratory and clinical status.
Caution is advised in newborns with severe complications affecting respiratory or circulatory stability.
Alternatives to Survanta
Curosurf
Infasurf
Surfaxin
Proper Use of Survanta
This medication should be administered only by a specialist physician or a qualified medical team within a hospital
environment, as its use requires specialized equipment and close patient monitoring.
Respiratory status, oxygen saturation, and vital signs should be monitored during and after administration. The
prescribed dose should be based on the infant’s weight and clinical condition.
The infant’s response should be carefully assessed after each dose to ensure treatment effectiveness and safety. The
product should not be used outside approved medical recommendations and established treatment protocols.
Storage Conditions
Store refrigerated according to the manufacturer's instructions.
Do not freeze.
Keep in the original package.
Protect from direct light.
Keep out of the reach of children.
Do not use after the expiration date.